GT201300040A - Quelatos de oligonucleótidos - Google Patents
Quelatos de oligonucleótidosInfo
- Publication number
- GT201300040A GT201300040A GT201300040A GT201300040A GT201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A GT 201300040 A GT201300040 A GT 201300040A
- Authority
- GT
- Guatemala
- Prior art keywords
- oligonucleotide
- divalent
- chelation
- cations
- cheats
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 7
- 150000001768 cations Chemical class 0.000 abstract 2
- 230000009920 chelation Effects 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000010100 anticoagulation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000001457 metallic cations Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37525710P | 2010-08-20 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300040A true GT201300040A (es) | 2014-09-02 |
Family
ID=45594559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300040A GT201300040A (es) | 2010-08-20 | 2013-02-14 | Quelatos de oligonucleótidos |
Country Status (35)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス， インコーポレイテッド | 遺伝子発現と疼痛 |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| PT2841578T (pt) | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| RU2668136C2 (ru) * | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| HUE054875T2 (hu) * | 2012-05-18 | 2021-10-28 | Replicor Inc | Oligonukleotid kelátkomplex-polipeptid készítmények és eljárások |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| CN104603271B (zh) * | 2012-07-03 | 2019-07-19 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
| CN104837501B (zh) | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| KR20170029577A (ko) | 2014-07-10 | 2017-03-15 | 레플리코르 인코포레이티드 | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 |
| CN106661578B (zh) | 2014-08-15 | 2020-08-04 | 埃迪恩克斯股份有限公司 | 用于疼痛治疗的寡核苷酸诱饵 |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| JP2018513127A (ja) | 2015-04-23 | 2018-05-24 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | 多価カチオン塩組成物を用いたポリヌクレオチド調製方法 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20200147124A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20230250125A1 (en) | 2020-04-01 | 2023-08-10 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| JP2024521897A (ja) * | 2021-06-02 | 2024-06-04 | アタランタ セラピューティクス，インコーポレーテッド | 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法 |
| CN117616121A (zh) | 2021-07-09 | 2024-02-27 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 寡核苷酸用于具有肾脏损伤的个体的用途 |
| EP4728073A1 (en) * | 2023-06-16 | 2026-04-22 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2300938A1 (en) * | 1997-08-20 | 1999-02-25 | Somagenics, Inc. | Antisense and antigene therapeutics with improved binding properties and methods for their use |
| JP3667047B2 (ja) * | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| WO2005023829A1 (ja) * | 2003-09-02 | 2005-03-17 | Japan Science And Technology Agency | 金属錯体型核酸 |
| WO2005026188A1 (ja) * | 2003-09-08 | 2005-03-24 | Japan Science And Technology Agency | 金属錯体型核酸 |
| WO2007005626A1 (en) * | 2005-07-01 | 2007-01-11 | Bioveris Corporation | Compositions and methods for detecting, amplifying, and/or isolating nucleic acids |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
-
2011
- 2011-08-18 JP JP2013524318A patent/JP5775581B2/ja active Active
- 2011-08-18 NZ NZ606364A patent/NZ606364A/en not_active IP Right Cessation
- 2011-08-18 PH PH1/2013/500192A patent/PH12013500192B1/en unknown
- 2011-08-18 LT LTEP11817618.9T patent/LT2605794T/lt unknown
- 2011-08-18 PT PT118176189T patent/PT2605794T/pt unknown
- 2011-08-18 US US13/212,306 patent/US8513211B2/en active Active
- 2011-08-18 KR KR20157007582A patent/KR20150039873A/ko not_active Withdrawn
- 2011-08-18 CN CN201410046103.1A patent/CN103768086B/zh not_active Expired - Fee Related
- 2011-08-18 MY MYPI2013000544A patent/MY160961A/en unknown
- 2011-08-18 CA CA2855690A patent/CA2855690C/en active Active
- 2011-08-18 KR KR1020157017340A patent/KR20150082685A/ko not_active Withdrawn
- 2011-08-18 HU HUE11817618A patent/HUE029521T2/en unknown
- 2011-08-18 DK DK11817618.9T patent/DK2605794T3/en active
- 2011-08-18 SG SG2013004957A patent/SG187165A1/en unknown
- 2011-08-18 EA EA201300259A patent/EA026660B1/ru unknown
- 2011-08-18 BR BR112013003875-6A patent/BR112013003875B1/pt not_active IP Right Cessation
- 2011-08-18 HR HRP20161333TT patent/HRP20161333T1/hr unknown
- 2011-08-18 RS RS20160869A patent/RS55245B1/sr unknown
- 2011-08-18 EP EP11817618.9A patent/EP2605794B1/en active Active
- 2011-08-18 CA CA2806616A patent/CA2806616C/en active Active
- 2011-08-18 ES ES11817618.9T patent/ES2598556T3/es active Active
- 2011-08-18 PL PL11817618T patent/PL2605794T3/pl unknown
- 2011-08-18 AU AU2011291401A patent/AU2011291401B2/en not_active Ceased
- 2011-08-18 MX MX2013001668A patent/MX340294B/es active IP Right Grant
- 2011-08-18 KR KR1020137007008A patent/KR101606495B1/ko not_active Expired - Fee Related
- 2011-08-18 SI SI201130985A patent/SI2605794T1/sl unknown
- 2011-08-18 WO PCT/CA2011/000956 patent/WO2012021985A1/en not_active Ceased
- 2011-08-18 CN CN201180035946.6A patent/CN103052405B/zh not_active Expired - Fee Related
-
2013
- 2013-01-15 IL IL224237A patent/IL224237A/en active IP Right Grant
- 2013-01-18 ZA ZA2013/00497A patent/ZA201300497B/en unknown
- 2013-02-11 CO CO13027675A patent/CO6670525A2/es unknown
- 2013-02-13 CL CL2013000445A patent/CL2013000445A1/es unknown
- 2013-02-14 GT GT201300040A patent/GT201300040A/es unknown
- 2013-02-14 DO DO2013000041A patent/DOP2013000041A/es unknown
- 2013-02-19 CR CR20130069A patent/CR20130069A/es unknown
- 2013-02-19 EC ECSP13012449 patent/ECSP13012449A/es unknown
- 2013-02-20 CU CU2013000022A patent/CU20130022A7/es unknown
- 2013-05-30 US US13/905,318 patent/US8716259B2/en active Active
-
2016
- 2016-10-13 SM SM201600370T patent/SMT201600370B/it unknown
- 2016-10-17 CY CY20161101037T patent/CY1118207T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20130022A7 (es) | Quelatos de oligonucleótidos | |
| AR091604A1 (es) | Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto | |
| NZ710444A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
| EP4335507A3 (en) | Combination therapy | |
| MX2015017532A (es) | Métodos para modular la actividad del regulador de transmembrana de fibrosis quística. | |
| MX373763B (es) | Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica. | |
| PE20160190A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
| EA201591767A8 (ru) | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии | |
| ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| PH12013500449A1 (en) | Treatment of diseases | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| UY31849A (es) | Nuevos compuestos como inhibidores de pde4 | |
| BR112012022243A2 (pt) | terapias inibidoras de autografia baseadas em tioxantona para tratar câncer | |
| CR20140367A (es) | Inhibidores de iap | |
| EA201600398A1 (ru) | Тиенопиримидины в качестве ингибиторов mknk1 и mknk2 | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| WO2014205127A3 (en) | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets | |
| FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
| MX374671B (es) | Complejo de zinc fosfato para el cuidado bucal. |